insights_auto
Pourquoi 688235 a-t-elle augmenté de 4,06%?
Approfondirchevron_right
688235:SHA
BeOne Medicines AG
255,98 CNY
arrow_upward
+4,06%(+9,99) 1J
16 oct., 15:00:00 UTC+8 · CNY
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour 688235...
Ouverture
253,20 CNY
Élevé
268,18 CNY
Faible
252,09 CNY
Cap. boursière
303,26 Md
Vol. moyen
2,81 M
Volume
5,69 M
Ratio cours/bénéfice
91,43
+ haut sur 1 an
319,24 CNY
+ bas sur 1 an
205,51 CNY
BPA
2,80 CNY
Nombre d'employés
12 k
Ouverture
253,20 CNY
Élevé
268,18 CNY
Faible
252,09 CNY
Cap. boursière
303,26 Md
Vol. moyen
2,81 M
Volume
5,69 M
Ratio cours/bénéfice
91,43
+ haut sur 1 an
319,24 CNY
+ bas sur 1 an
205,51 CNY
BPA
2,80 CNY
Nombre d'employés
12 k
Articles
Sources : Web et partenaires du secteur de l'information
ad-hoc-news.de
·
il y a 13 heures
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
À propos de BeOne Medicines AG
PDGJohn Vincent Oyler | John Vincent Oyler
Employés12 k
Date de création28 oct. 2010
Siège social-
Secteur-
Site Webbeonemedicines.com